^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR T790M

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    22h
    Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) (clinicaltrials.gov)
    P3, N=390, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2026 --> Feb 2027 | Trial primary completion date: Oct 2026 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement
    |
    erlotinib
    1d
    Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC (clinicaltrials.gov)
    P1, N=16, Terminated, Rutgers, The State University of New Jersey | Active, not recruiting --> Terminated; accrual goal met
    Trial termination
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • LAG3 (Lymphocyte Activating 3) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD27 (CD27 Molecule)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement
    |
    Tecentriq (atezolizumab) • varlilumab (CDX 1127)
    3d
    HBE-843, a Novel, Potent, and Selective EGFR Targeting PROTAC for the Treatment of Non-Small-Cell Lung Cancer. (PubMed, Arch Pharm (Weinheim))
    In vivo studies demonstrated a 112% tumor growth inhibition in L858R-induced cancers. These findings suggest that HBE-843 holds promise as a lead compound for developing new drugs to overcome C797S mutant-mediated resistance in clinical settings.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CRBN (Cereblon)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR wild-type
    6d
    TATTON: AZD9291 in Combination With Ascending Doses of Novel Therapeutics (clinicaltrials.gov)
    P1, N=344, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • Orpathys (savolitinib) • simmitinib (SYHA1817)
    7d
    Adjuvant osimertinib following SBRT in patients with unresected EGFRm stage I-II lymph node-negative (T1-3N0M0) NSCLC ： A Phase II, Prospective, Multicenter, Interventional study (SPACE) (ChiCTR2500111875)
    P=N/A, N=60, Not yet recruiting, Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute); Shandong First Medical University
    New trial
    |
    CD4 (CD4 Molecule)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)
    7d
    Exploratory clinical study on preserving organs in patients with stage II-III non-small cell lung cancer(The Future Star) (ChiCTR2500115167)
    P4, N=598, Recruiting, Jiangsu Cancer Hospital; Jiangsu Cancer Hospital
    New P4 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • ALK mutation
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Ensacove (ensartinib) • Ameile (aumolertinib) • AiRuiLi (adebrelimab)
    7d
    Clinical Study of ctDNA Dynamic Monitoring in Sacituzumab tirumotecan for EGFR-Mutated Non-Squamous NSCLC After EGFR-TKI Failure (ChiCTR2600115950)
    P4, N=30, Not yet recruiting, Shaanxi Provincial Cancer Hospital; Shaanxi Provincial Cancer Hospital
    New P4 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Jiataile (sacituzumab tirumotecan)
    7d
    An exploratory study of Sacituzumab Tirumotecan in the treatment of EGFR-mutated platinum-based chemotherapy-resistant transformed small cell lung cancer (ChiCTR2500113126)
    P2, N=39, Not yet recruiting, Dongguan People's Hospital; Dongguan People's Hospital
    New P2 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR positive
    |
    Jiataile (sacituzumab tirumotecan)
    7d
    A Single-Arm, Multicenter, Phase II Clinical Trial of Firmonertinib in Combination With Definitive Radiotherapy for Patients With Stage III Unresectable Pulmonary Adenocarcinoma Harboring Positive EGFR Uncommon Driver Mutations (ChiCTR2500114582)
    P2, N=15, Not yet recruiting, Hunan Cancer Hospital; Hunan Cancer Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Ivesa (firmonertinib)
    7d
    Limertinib Plus Platinum-Based Chemotherapy in Patients with Advanced EGFR-Mutated Non-Squamous NSCLC after Progression on First-Line EGFR-TKI Therapy : A Single-Arm, Multicenter Study (ChiCTR2500114831)
    P2, N=61, Not yet recruiting, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
    New P2 trial
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    cisplatin • carboplatin • pemetrexed • limertinib (ASK120067)
    7d
    A phase II clinical study of ivosimab combined with third-generation EGFR-TKIs in the treatment of advanced non-small cell lung cancer with slow progression and potential progression during EGFR-TKIs therapy (ChiCTR2500113360)
    P2/3, N=36, Not yet recruiting, Shandong First Medical University Affiliated Tumor Hospital; Shandong First Medical University Affiliated Tumor Hospital
    New P2/3 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    7d
    A First-In-Human, Multicenter, Open-Label Phase I/II Investigational Study to Evaluate the Safety, Tolerability, Pharmacokinetics, And Preliminary Efficacy of KY-0301 as monotherapy or combined with other anticancer agents in Patients with advanced Solid Tumors (ChiCTR2600116103)
    P1/2, N=120, Recruiting, Shanghai East Hospital; Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • KRAS mutation • EGFR mutation • MSI-H/dMMR • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR wild-type • MET exon 14 mutation • KRAS wild-type • RAS wild-type • ROS1 fusion • ROS1 rearrangement • MET mutation • NTRK fusion